Logo

Polpharma & Bioeq Report BLA Submission to the US FDA for FYB201 (biosimilar- ranibizumab)

Share this
Polpharma & Bioeq Report BLA Submission to the US FDA for FYB201 (biosimilar- ranibizumab)

Polpharma & Bioeq Report BLA Submission to the US FDA for FYB201 (biosimilar- ranibizumab)

Shots:

  • Polpharma has reported that its JV company- Bioeq has submitted a BLA for FYB201 (biosimilar referencing Lucentis) to the FDA. FYB201 was originally licensed from Formycon AG
  • The launch of biosimilar ranibizumab may increase market competition- reduce cost and expand patient access with proven analytical & clinical similarity to Lucentis
  • Lucentis is a mAb fragment used to treat various types of macular-degenerative diseases including wet AMD- DR- macular edemas and MCNV. If approved- Coherus will commercialize FYB201 in the US

  | Ref: Businesswire | Image: Businesswire

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions